Open AccessCXCR3 Antagonist NBI-74330 Attenuates Atherosclerotic Plaque Formation in LDL Receptor–Deficient Mice
Author(s) -
Eva J.A. van Wanrooij,
Saskia C.A. de Jager,
Thomas van Es,
Paul de Vos,
Helen L. Birch,
David Owen,
Robbert J. Watson,
Erik A.L. Biessen,
Gayle A. Chapman,
Theo J.C. van Berkel,
Johan Kuiper
Publication year - 2007
Publication title -
arteriosclerosis thrombosis and vascular biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.007
H-Index - 270
eISSN - 1524-4636
pISSN - 1079-5642
DOI - 10.1161/atvbaha.107.147827
Subject(s) - cxcr3 , lesion , lymph , medicine , inflammation , chemokine receptor , antagonist , foam cell , chemokine , receptor , pathology , endocrinology , lipoprotein , cholesterol
The chemokine receptor CXCR3 is implicated in migration of leukocytes to sites of inflammation. Antagonizing CXCR3 may be a strategy to inhibit inflammation-induced leukocyte migration and subsequently reduce atherosclerosis. We used the CXCR3 specific antagonist NBI-74330 to block CXCR3-mediated signaling in peritonitis and diet-induced atherosclerosis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom